AU2015254669A1 - Nitisinone dosing regimens for the treatment of alkaptonuria - Google Patents

Nitisinone dosing regimens for the treatment of alkaptonuria Download PDF

Info

Publication number
AU2015254669A1
AU2015254669A1 AU2015254669A AU2015254669A AU2015254669A1 AU 2015254669 A1 AU2015254669 A1 AU 2015254669A1 AU 2015254669 A AU2015254669 A AU 2015254669A AU 2015254669 A AU2015254669 A AU 2015254669A AU 2015254669 A1 AU2015254669 A1 AU 2015254669A1
Authority
AU
Australia
Prior art keywords
nitisinone
dose
administered
hga
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015254669A
Other languages
English (en)
Inventor
Birgitta Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum International AB
Original Assignee
Swedish Orphan Biovitrum International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum International AB filed Critical Swedish Orphan Biovitrum International AB
Publication of AU2015254669A1 publication Critical patent/AU2015254669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015254669A 2014-04-30 2015-04-29 Nitisinone dosing regimens for the treatment of alkaptonuria Abandoned AU2015254669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450521-8 2014-04-30
SE1450521 2014-04-30
PCT/EP2015/059352 WO2015165972A1 (en) 2014-04-30 2015-04-29 Nitisinone dosing regimens for the treatment of alkaptonuria

Publications (1)

Publication Number Publication Date
AU2015254669A1 true AU2015254669A1 (en) 2016-12-15

Family

ID=53175441

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015254669A Abandoned AU2015254669A1 (en) 2014-04-30 2015-04-29 Nitisinone dosing regimens for the treatment of alkaptonuria

Country Status (11)

Country Link
US (1) US20170049716A1 (enExample)
EP (1) EP3137066A1 (enExample)
JP (1) JP2017514820A (enExample)
AU (1) AU2015254669A1 (enExample)
BR (1) BR112016024756A2 (enExample)
CA (1) CA2947062A1 (enExample)
IL (1) IL248506A0 (enExample)
MA (1) MA39918A (enExample)
SG (1) SG11201608957VA (enExample)
TN (1) TN2016000479A1 (enExample)
WO (1) WO2015165972A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838039C (en) * 2011-06-23 2017-10-24 Swedish Orphan Biovitrum International Ab Liquid pharmaceutical composition comprising nitisinone

Also Published As

Publication number Publication date
JP2017514820A (ja) 2017-06-08
SG11201608957VA (en) 2016-11-29
MA39918A (fr) 2017-03-08
EP3137066A1 (en) 2017-03-08
WO2015165972A1 (en) 2015-11-05
IL248506A0 (en) 2016-12-29
BR112016024756A2 (pt) 2017-08-15
US20170049716A1 (en) 2017-02-23
CA2947062A1 (en) 2015-11-05
TN2016000479A1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
AU2023233141B2 (en) Method of treatment with tradipitant
US20190083388A1 (en) Synthentic transdermal cannabidiol for the treatment of focal epilepsy in adults
AU2011334617B2 (en) Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
US10188635B2 (en) Use of gaboxadol in the treatment of tinnitus
US20200101067A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
CN114728012A (zh) 用于治疗癫痫持续状态的加奈索酮
US10226420B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
JP2015523986A5 (enExample)
US9226926B2 (en) Therapeutic agent for lower urinary tract disease
AU2015254669A1 (en) Nitisinone dosing regimens for the treatment of alkaptonuria
RU2369393C2 (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
RU2499597C2 (ru) Способ лечения и профилактики назальной обструкции у больных полипозным риносинуситом
Ghimire et al. Comparative efficacy of steroid nasal spray versus antihistamine nasal spray in allergic rhinitis
EA029932B1 (ru) Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции
EP4403181A1 (en) A medicinal product for use in administering in the treatment, control and/or prevention of pain
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
Hryniuk Treatment optimization of non-alcoholic steatohepatitis in obese patients according to comorbidity with COPD
WO2013062441A1 (ru) Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
Dewinter The continuous search for new approaches improving postoperative outcomes
US20070142395A1 (en) Treatment of sexual dysfunction with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof
HK40003409A (en) Treatment of prurigo nodularis

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period